Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 17:25:32 01/06/2026 BST			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 88.88K 82.76K 76.12K 143K 9.68M 145K 982K 384K 4.8M 380K 372K 16.58M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.95M 9.26M 8.52M 15.97M 1.08B 16.24M 110M 43.01M 537M 42.55M 41.63M 1.86B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
21/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/10/25	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/08/25	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
30/04/25	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
29/04/25	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
16/11/24	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
17/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
15/10/24	Top Midday Decliners	MT
14/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
27/09/24	Top Midday Decliners	MT
24/09/24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24/09/24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

21/09/23	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
21/09/23	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
21/09/23	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
16/05/23	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
24/03/23	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Share Price

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

22/11/24	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24/10/24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24/10/24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/10/24	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/10/24	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		6,374.41
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	31/12/2018
Michael Golembiewski DFI	Director of Finance/CFO	54	31/08/2021
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/02/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
12/01/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%
12/01/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	-.--%	-100.00%	136
ARGENX SE	-2.25%	+2.44%	+53.17%	+64.57%	56.19B
WUXI APPTEC CO., LTD.	-1.32%	-0.97%	+38.41%	+77.52%	54.83B
BIONTECH SE	+1.49%	+0.31%	-19.82%	-11.95%	23.04B
INSMED INCORPORATED	-0.57%	-2.70%	+0.17%	+410.44%	22.7B
WUXI BIOLOGICS (CAYMAN) INC.	-0.21%	+0.84%	+22.48%	-7.92%	20.23B
GENMAB A/S	0.00%	+3.30%	+28.01%	-29.07%	17.83B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.97%	+0.89%	+37.28%	+539.62%	15.65B
PHARMAESSENTIA CORPORATION	-6.69%	-5.11%	+166.00%	+304.89%	15.24B
EXELIXIS, INC.	+1.25%	+1.76%	+23.93%	+188.32%	14.03B
Average	+989.07%	-0.02%	+34.96%	+143.64%	23.97B
Weighted average by Cap.	-1.17%	+0.42%	+37.72%	+133.38%

	2022	2023
Net sales	-	2.2 1.93 1.8 1.66 3.1 210.47 3.16 21.36 8.36 104.38 8.27 8.09 360.62
Net income	-73.53M -64.53M -60.09M -55.27M -104M -7.03B -105M -713M -279M -3.48B -276M -270M -12.04B	-37.88M -33.25M -30.96M -28.47M -53.38M -3.62B -54.29M -367M -144M -1.79B -142M -139M -6.2B
Net Debt	4.59M 4.03M 3.75M 3.45M 6.47M 438M 6.58M 44.49M 17.41M 217M 17.23M 16.86M 751M	11.23M 9.86M 9.18M 8.44M 15.83M 1.07B 16.1M 109M 42.62M 532M 42.17M 41.26M 1.84B